Table 2 Parameters assessed before and 3 months after hysterectomy, ulipristal acetate therapy or uterine artery embolization
Baseline | 3 months follow-up | P | |
|---|---|---|---|
AFC Hysterectomy | 14 (12–24) | 14 (9–19) | > 0.05 |
AFC UPA | 15 (13–24) | 15 (12–19) | > 0.05 |
AFC UAE | 19 (15–24) | 8 (4–12) | < 0.001 |
AMH Hysterectomy | 2.64 (2.03–3.84) | 2.66 (1.91–3.67) | > 0.05 |
AMH UPA | 2.89 (2.11–4.34) | 2.91 (2.22–4.12) | > 0.05 |
AMH UAE | 3.04 (2.53–3.7) | 1.28 (0.49–2.11) | < 0.001 |
INHB Hysterectomy | 28.09 (20.76–35.33) | 24.05 (18.79–32.74) | < 0.001 |
INHB UPA | 25.16 (14.78–47.34) | 26.78 (13.78–42.33) | > 0.05 |
INHB UAE | 25.11 (15.67–33.9) | 10.78 (4.71–15.83) | < 0.001 |
FSH Hysterectomy | 8.32 (5.51–13.47) | 9.6 (5.62–12.59) | > 0.05 |
FSH UPA | 11.21 (4.56–16.78) | 9.88 (6.12–19.34) | > 0.05 |
FSH UAE | 8.75 (6.3–11.12) | 16.99 (12.35–41.33) | < 0.001 |
E2 Hysterectomy | 81.85 (73.62–108.12) | 74.59 (59.34–115.43) | 0.005 |
E2 UPA | 90.23 (78.34–136.45) | 94.32 (67.22–154.33) | > 0.05 |
E2 UAE | 98.44 (87.32–115.89) | 57.37 (39.34–93.22) | < 0.001 |